c/survodutide · created 14 Feb 2024
GLP-1/glucagon dual agonist. MASH data and the hepatic angle.
Thinking out loud about this: phase 2 biopsy endpoints, and what "resolution" means. The honest evidence position, written out so this board does not drift. Phase 2…
The phase 2 MASH results ( NEJM , 2024) are, to me, the most underdiscussed thing in this whole space. Biopsy-confirmed endpoints. Not an ALT screenshot, not imaging,…
survodutide MASH data is the most interesting hepatic readout in the class. Change my mind, genuinely — I have no stake in being right about this. Nothing containing…
Something I keep coming back to: glucagon co-agonism has its own safety story, stop generalising from tirz. Bought small because the evidence base is early. That is the…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsSurvodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference